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Abstract. 
 
Several recent studies suggest the isolation of 
stem cells in skeletal muscle, but the functional proper-
ties of these muscle-derived stem cells is still unclear. In 
the present study, we report the puriﬁcation of muscle-
 
derived stem cells from the 
 
mdx
 
 mouse, an animal 
model for Duchenne muscular dystrophy. We show that 
 
enrichment of desmin
 
1
 
 cells using the preplate tech-
nique from mouse primary muscle cell culture also en-
riches a cell population expressing CD34 and Bcl-2. The 
CD34
 
1
 
 cells and Bcl-2
 
1
 
 cells were found to reside 
within the basal lamina, where satellite cells are nor-
mally found. Clonal isolation and characterization from 
this CD34
 
1
 
Bcl-2
 
1
 
 enriched population yielded a puta-
tive muscle-derived stem cell, mc13, that is capable of 
differentiating into both myogenic and osteogenic lin-
eage in vitro and in vivo. The mc13 cells are c-kit and 
CD45 negative and express: desmin, c-met and MNF, 
three markers expressed in early myogenic progenitors; 
Flk-1, a mouse homologue of KDR recently identiﬁed 
in humans as a key marker in hematopoietic cells with 
stem cell-like characteristics; and Sca-1, a marker for 
both skeletal muscle and hematopoietic stem cells. In-
tramuscular, and more importantly, intravenous injec-
tion of mc13 cells result in muscle regeneration and 
partial restoration of dystrophin in 
 
mdx
 
 mice. Trans-
plantation of mc13 cells engineered to secrete osteo-
genic protein differentiate in osteogenic lineage and ac-
celerate healing of a skull defect in SCID mice. Taken 
together, these results suggest the isolation of a popula-
tion of muscle-derived stem cells capable of improving 
both muscle regeneration and bone healing.
Key words: dystrophin • gene transfer • BMP-2 • 
stem cells • bone formation
 
Introduction
 
The development of muscle stem cells for transplantation or
gene transfer (ex vivo approach) as a new method for treat-
ment of patients with muscle disorders has become more
attractive and challenging in the past few years (Barroffio
et al., 1996; Cornelison and Wold, 1997; Gussoni et al., 1999;
Miller et al., 1999). Duchenne muscular dystrophy (DMD)
 
1
 
is a progressive muscle weakness characterized by a lack
of dystrophin expression at the sarcolemma of muscle fi-
bers (Hoffman et al., 1987; Bonilla et al., 1988; Watkins et al.,
1988; Zubryzcka-Gaarn et al., 1988; Arahata et al., 1989).
Dystrophin is associated with a large oligomeric complex
of glycoprotein called dystrophin-associated protein (DAPs),
which provide linkage to the extracellular matrix (Ervasti
and Campbell, 1991). Although the transplantation of
myoblasts has been found capable of transiently delivering
dystrophin and improving the strength of injected dystro-
phic muscle, this approach has been hindered by various
limitations: immune rejection, poor cellular survival, and the
limited spread of the injected cells (Morgan et al., 1988,
1990, 1993; Karpati et al., 1989, 1992; Partridge et al., 1989;
Partridge, 1991; Gussoni et al., 1992, 1997; Huard et al.,
1992a,b, 1994a,b,c; Tremblay et al., 1993; Beauchamps et
al., 1994, 1999; Kinoshita et al., 1994; Mendell et al., 1995;
Vilquin et al., 1995; Fan et al., 1996; Guerette et al., 1997;
Qu et al., 1998; Qu and Huard, 2000a,b).
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Abbreviations used in this paper:
 
 adBMP-2, adenovirus bone morpho-
genetic protein-2 construct; ALP, alkaline phosphatase; DAPI, 4
 
9
 
,6-dia-
minido-2-phenylindole; DMD, Duchenne muscular dystrophy; MNF, myo-
cyte nuclear factor; npmc, nonpurified muscle-derived cells; pp, preplate;
rhBMP-2, recombinant human BMP-2; RT, reverse transcription.  
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The efficiency of cell transfer might be improved by using
muscle stem cells, which potentially display unique features,
including: self-renewing cells that produce progeny; arise
early in development and persist throughout life; and long-
term proliferation and multipotency. In fact, muscle satellite
cells have long been considered the myogenic cells responsi-
ble for postnatal muscle growth, regeneration and repair for
the maintenance of skeletal muscle (Bischoff, 1994). How-
ever, the recent isolation of cells from bone marrow (Ferrari
et al., 1998; Bittner et al., 1999; Gussoni et al., 1999) and the
embryonic vasculature (De Angelis et al., 1999) that are
capable of differentiating in the myogenic lineage led us to
question whether the satellite cells are the only cells capable
of supporting muscle growth and regeneration in postnatal
life (see review by Seale and Rudnicki, 2000).
It has been established that mesenchymal stem cells de-
rived from bone marrow (Caplan, 1991; Pittenger et al.,
1999) and other connective tissues (Young et al., 1993,
1995; Lucas, et al., 1995) have the potential to differentiate
into different lineage upon changes in external stimuli.
Skeletal muscle tissue has been extensively investigated as
a potential source for isolation of pluripotent stem cells
(Katagiri et al., 1995; Cornelison and Wold, 1997; Gussoni
et al., 1999; Jackson et al., 1999; Bosch et al., 2000). In par-
ticular, stem cell populations from muscle and nonstromal
fraction of bone marrow were recently shown to partially
restore the expression of dystrophin in the 
 
mdx
 
 mouse, an
animal model of DMD (Gussoni et al., 1999). Also, a myo-
genic cell line from mouse skeletal muscle has been shown
to differentiate into osteoblastic lineage in vitro upon
stimulation with bone morphogenetic protein, a class of
proteins intimately involved in growth and differentiation
of mesenchymal cells (Katagiri et al., 1995). Thus, at least
one subpopulation of cells within skeletal muscle can dif-
ferentiate into multiple lineages.
The satellite cells, a subpopulation of muscle-derived cells,
may have stem cell-like characteristics (Baroffio et al.,
1996). When cultured in a monolayer system, subpopula-
tions of satellite cells remain mononucleated and desmin
positive, dividing to produce fusing and nonfusing myo-
blasts (Baroffio et al., 1996). When transplanted into a host
muscle, myoblasts can either fuse with host myofibers or
fuse together into myotubes that will consequently differ-
entiate into muscle fibers (Morgan et al., 1988, 1990, 1993;
Karpati et al., 1989, 1992; Partridge 1991; Gussoni et al.,
1992, 1997; Huard et al., 1992a,b, 1994a,b,c; Tremblay et al.,
1993; Beauchamps et al., 1994, 1999; Kinoshita et al., 1994;
Mendell et al., 1995; Vilquin et al., 1995; Fan et al., 1996;
Guerette et al., 1997; Qu et al., 1998; Qu and Huard,
2000a,b). However, the vast majority of transplanted myo-
blasts die rapidly after the injection (Beauchamps et al.,
1994, 1999; Huard et al., 1994c; Fan et al., 1996; Qu et al.,
1998), which may be partly related to inflammatory reac-
tions (Guerette et al., 1997). Although an improvement of
cell survival was achieved by blocking inflammation, a dra-
matic loss of injected cells was still observed (Guerette et al.,
1997; Qu et al., 1998).
A recent report has suggested that only a discrete mi-
nority of myoblasts can survive after implantation and
thus may represent a population of myogenic stem cells
(Beauchamps et al., 1999). Indeed, we have recently id-
entified a specific population of highly purified muscle-
 
derived cells by the preplate technique that significantly
improved cell survival after transplantation when injected
intramuscularly (Qu et al., 1998). Although the mechanism
by which these specific muscle-derived cells display a high
cell survival is unclear, their ability to rapidly fuse with
various types of host myofibers may help to improve their
survivability in skeletal muscle (Qu et al., 1998). In fact,
we have recently observed that the fusion of myoblasts
with host myofibers after transplantation is muscle fiber-
dependent (Qu and Huard, 2000a,b). Our results suggest
that myoblasts fuse with myofibers expressing the same
type of myosin heavy chains (MyHCs); consequently,
matching host muscle and donor myoblasts for MyHCs
improves myoblast transfer therapy (Qu and Huard,
2000a,b). Alternatively, the use of these specific muscle-
derived cells that can fuse with both types of myofibers
can also be used to improve the efficiency of myoblast
transplantation (Qu and Huard, 2000a,b).
Taken together, these results suggest that satellite cells
are highly heterogeneous in nature. This prompted our at-
tempt to investigate whether our highly purified muscle-
derived cells (preplate technique) will express markers of
stem cells and differentiate into osteogenic lineage. In this
report, we show that the highly purified myogenic cells de-
rived by the preplate technique express markers indicative
of stem cells. Isolation and characterization of a clonal
population from these highly purified myogenic cells re-
vealed that a clonal cell population (mc13) express both
stem cell and satellite cell-specific markers. More impor-
tantly, the mc13 cells have the capacity to differentiate
into both myogenic and osteogenic lineage in vitro and in
vivo. Thus, our results suggest that a subpopulation of
muscle-derived cells possess stem cell-like characteristics
and can differentiate into multiple lineages.
 
Materials and Methods
 
Isolation of Muscle-derived Cells
 
Primary muscle cells were isolated from 3-wk-old 
 
mdx
 
 mice (C57BL/
10ScSn mdx/mdx, The Jackson Laboratory) using a technique previously
described (Rando and Blau, 1994; Qu et al., 1998). The isolated cells were
then suspended in the growth medium (DME supplemented with 10%
FBS, 10% horse serum, 0.5% chick embryo extract, and 2% penicillin/
streptomycin). The cells were then preplated in collagen-coated flasks
(Rando and Blau, 1994; Qu et al., 1998). After
 
 z
 
1 h, the supernatant was
withdrawn from the flask and replated in a fresh collagen-coated flask. The
cells that adhered rapidly within this 1-h incubation were mostly fibroblasts
(Rando and Blau, 1994; Qu et al., 1998; Qu and Huard, 2000a,b). The serial
replating of the supernatant was repeated when 30–40% of the cells had
adhered to each flask. After 
 
z
 
5–6 serial platings, the culture was enriched
with small, round cells (pp6; Qu et al., 1998; Qu and Huard, 2000a,b).
 
Clonal Isolation of Purified Muscle-derived Cells
 
To isolate clones from pp6, the slow adhering primary muscle cells were
transfected with a plasmid encoding for the 
 
b
 
-galactosidase, minidystro-
phin (Yuasa et al., 1998; gift from Dr. Takeda, Kumamoto University
School of Medicine, Kumamoto, Japan) and the neomycin resistance gene.
The highly purified muscle-derived cells were transfected with 10 
 
m
 
g of the
linear plasmid containing minidystrophin, 
 
lacZ
 
, and neomycin resistance
gene using the lipofectamine reagent (GIBCO BRL) according to the man-
ufacturer’s instructions. At 72 h after transfection, cells were selected with
3,000 
 
m
 
g/ml of G418 (GIBCO BRL) for 10 d until colonies appeared. Colo-
nies were then picked up after transfection, expanded to obtain large quan-
tity of the transfected cells, and tested for expression of 
 
lacZ
 
 and dystro-
phin genes. One of these clones, mc13, was chosen for further study. 
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We have recently investigated two additional clones of muscle-derived
cells from the highly purified muscle-derived cells (pp6). These clones of
muscle-derived cells (MD1 and MD2) were not transfected by the plasmid
that encodes for the minidystrophin, 
 
lacZ
 
, and neomycin resistance genes.
These cells were cloned using a limiting dilution derived technique by
which the cells from the preplate #6 (pp6) population were: seeded at a
low density in culture flasks; cultivated for 1 wk until colonies appeared;
and single colonies were then trypsinized and the detached cells from the
individual colonies picked up and seeded in a culture flask. The expansion
of these new clonal cells in large quantity was performed using a similar
protocol as described for mc13.
 
Immunohistochemistry on Muscle Cells In Vitro
 
Cells were plated in a 6-well culture dish and fixed with cold methanol for
1 min. After rinsing with PBS, cells were blocked with 5% horse serum at
room temperature for 1 h. The primary antibodies were diluted in PBS as
follows: antidesmin (1:100; Sigma-Aldrich), biotinylated anti-mouse CD34
(1:200; BD PharMingen), rabbit anti–mouse Bcl-2 (1:1,000; BD PharMin-
gen); rabbit anti–mouse m-cadherin (1:50); mouse anti–mouse MyoD
(1:100; BD PharMingen); mouse anti–rat myogenin (1:100; BD PharMin-
gen); rabbit anti–mouse Flk-1 (1:100; Research Diagnostics); and biotin-
ylated anti-Sca-1 (1:200; BD PharMingen). The primary antibodies were
applied overnight at room temperature. Appropriate biotinylated second-
ary antibodies for nonbiotinylated primary antibodies were applied for 1 h
at room temperature. The cells were rinsed with PBS then incubated at
room temperature with 1/300 streptavidine conjugated with Cy3 fluoro-
chrome for 1 h. The cells were visualized by fluoroscopy, and the percent-
age of positive cells was calculated by counting positively stained cells in
10 randomly chosen 20
 
3
 
 fields.
 
RT-PCR Analysis of Muscle-derived Cells
 
Total RNA was isolated using TRIzol reagent (Life Technologies). Re-
verse transcription (RT) was carried out using SuperScript™ preamplifi-
cation system for first strand cDNA synthesis (Life Technologies) accord-
ing to the instructions of the manufacturer. PCR amplification of the
targets was performed in 50 
 
m
 
l reaction mixture containing 2 
 
m
 
l of RT ma-
terial, 5 U/100 
 
m
 
l Taq DNA polymerase (Life Technologies), and 1.5 mM
MgCl
 
2
 
. CD34 primers were designed by using Oligo software. The se-
quences of the other primers are from references as follows: myogenin (Roh-
wedel et al., 1995); c-met (Cornelison and Wold, 1997); and MNF (Yang
et al., 1997). The following parameters were used: 94
 
8
 
C 45 s, 50
 
8
 
C (for
CD34) 60 s; 60
 
8
 
C (for myogenin and c-met) 60 s; and 58
 
8
 
C (for MNF) 60 s,
72
 
8
 
C 90 s for 40 cycles. PCR products were checked by 1% agarose-TBE-
ethidium bromide gels. The expected products sizes are: CD34, 147 bp;
myogenin, 86 bp; c-met, 370 bp; and MNF, 305 bp. To exclude genomic
DNA contamination, two controls were used: parallel RT without reverse
transcriptase, and amplification of 
 
b
 
-actin using a primer set that spans an
intron (CLONTECH Laboratories, Inc.).
 
Cell Characterization by Flow-cytometry Analysis 
 
Cultures of muscle-derived cells were harvested before analysis with a 1:2
dilution of trypsin/EDTA solution diluted in HBSS (0.5% trypsin/5.3 mM
EDTA initial concentration; Life Technologies). Cells were then spun,
washed, counted, and divided into two groups (experimental and control).
A 1:10 mouse serum (Sigma-Aldrich) in PBS solution (0.5% BSA, 0.1%
sodium azide) and Fc Block (rat anti–mouse CD16/CD32; BD PharMin-
gen) were added to each cell pellet for 10 min on ice. Optimal amounts of
rat anti–mouse mAbs were predetermined and added directly to each tube
for 30 min. Each experimental tube received FITC-conjugated CD45,
R-PE–conjugated CD117(c-kit) and biotin-conjugated Sca-1 (all from BD
PharMingen). A control tube for each cell type received equivalent
amounts of FITC-conjugated, biotin-conjugated, and R-PE-conjugated iso-
type standards (BD PharMingen). After several rinses, streptavidin allo-
phycocyanin conjugate (APC; BD PharMingen) was added to each tube,
including controls, and incubated on ice for 20 min. Just before analysis,
7-amino-actinomycin D (7-AAD, Via-Probe, BD PharMingen) was added
to each tube for dead cell exclusion. A minimum of 10,000 live cell events
were analyzed on a FACSCalibur (Becton Dickinson) flow cytometer.
 
Immunohistochemistry on Muscle Tissue In Vivo
 
The cryosections of muscle samples from a 4-wk-old normal mouse (C-57
BL/6J, The Jackson Laboratory) was fixed with cold acetone for 2 min
 
and preincubated in 5% horse serum diluted in PBS for 1 h. For CD34,
Bcl-2, and laminin/collagen type IV, the following primary antibodies
were used: biotin anti-mouse CD34 (1:200 in PBS; BD PharMingen); rab-
bit anti–mouse Bcl-2 (1:1,000; BD PharMingen); and rabbit antilaminin
(1:100 in PBS; Sigma-Aldrich) or anti–mouse collagen type IV (1:100 in
PBS; Chemicon). The CD34 and Bcl-2 was also colocalized with Hoechst
33258 (bis-Benzimide, 1/100 in PBS; Sigma-Aldrich) to stain the nuclei.
For dystrophin staining, sheep anti–human D-10 antibody (1:250 dilution
in PBS) was used as the primary antibody. After several rinses in PBS, a
biotin-conjugated anti-sheep was subsequently used (1:250 dilution in
PBS). Streptavidin-FITC (bone) and streptavidin-Cy3 (muscle) at a dilu-
tion of 1:250 dilution in PBS were used; immunoreaction was observed by
fluorescence microscopy (Nikon, Eclipse E-800). Finally, the colocaliza-
tion of 
 
b
 
-galactosidase, osteocalcin, and 4
 
9
 
,6-diaminido-2-phenylindole
(DAPI; Sigma-Aldrich) stain nuclei was performed using the following
protocol. The muscle sections were incubated with DAPI at a dilution
of 1/100 in PBS to stain the nuclei; a biotinylated anti–
 
b
 
-galactosidase an-
tibody (1/100 in PBS; Sigma-Aldrich), followed by streptavidin conjugated
to fluorescein (Gal-13, 1/300 in PBS; Sigma-Aldrich) to stain the 
 
b
 
-galac-
tosidase expressing nuclei; and a goat anti–mouse osteocalcin (1:100 in
PBS; Chemicon Co), followed by an incubation with a Cy3-conjugated
anti-goat antibody (1/100 in PBS; Sigma-Aldrich) to label the osteocalcin
expressing cells. The colocalization of the cells expressing 
 
b
 
-galactosidase,
osteocalcin with the nuclear labeling was visualized by fluorescence mi-
croscopy using an E-800 Nikon microscope.
 
Stimulation with rhBMP-2, Osteocalcin Staining, and 
Alkaline Phosphatase Assay
 
The mc13 and nonpurified muscle-derived cells (npmc) were plated in
triplicate at a density of 1–2 
 
3
 
 10
 
4
 
 per well in 12-well collagen-coated
flasks. The cells were stimulated by addition of 200 ng/ml recombinant hu-
man BMP-2 (rhBMP-2) to the media. The media was changed on days 1,
3, and 5 after initial plating. The control group also had media changed on
these days, without rhBMP-2. After 6 d of rhBMP-2 stimulation, cells
were counted using a hemacytometer, and cell lysates were harvested by
repeated freeze-thaw cycles. The alkaline phosphatase activity in the cell
lysate was measured using a commercially available kit (Sigma-Aldrich)
that utilizes color change in the reagent due to the hydrolysis of inorganic
phosphate from p-nitrophenyl phosphate. The color change was analyzed
on a spectrophotometer, and the data was expressed in international units:
ALP activity per liter normalized to 10
 
6
 
 cells (U/L/mil cells). Statistical
difference among the different groups was analyzed using 
 
t
 
 test (*
 
P 
 
,
 
0.05). The mc13 cells with or without rhBMP-2 stimulation were also ana-
lyzed on day 6 for expression of desmin. The desmin immunoreactivity
was determined with a mouse antidesmin (1:100; Sigma-Aldrich), fol-
lowed by a biotinylated anti-mouse (1/100; Sigma-Aldrich), and finally a
streptavidin-conjugated Cy3 (1/300; Sigma-Aldrich). The immunofluores-
cence was visualized by an inverted miscropscope (Diaphot, Nikon); the
number of desmin expressing cells were monitored and compared be-
tween the rhBMP-2 stimulated and nonstimulated cells.
 
In Vivo Differentiation of Muscle-derived Cells in 
Myogenic and Osteogenic Lineages
 
Myogenic. 
 
The mc13 cells were injected (5 
 
3
 
 10
 
5
 
 cells) intramuscularly in
the hind limb muscle of 
 
mdx
 
 mice. The 
 
mdx
 
 mice were killed at 7 d after
injection, and the injected muscles were frozen, cryostat sectioned, and as-
sayed for dystrophin (see above) and LacZ expression (Qu et al., 1998).
The mc13 cells (5 
 
3
 
 10
 
5
 
 cells) were also injected intravenously in the tail
vein of 
 
mdx
 
 mice. The mice were killed at 7 d after injection and various
tissues, including the hind limb muscle, lung, liver, spleen, kidney, and
brain, were isolated and assayed for dystrophin and LacZ using the same
protocol described above.
 
Osteogenic. 
 
The mc13 and npmc were transduced with an adenovirus
encoding for rhBMP-2 and injected intramuscularly in the hind limb mus-
cles of SCID
 
 
 
mice. Genetics Institute, Cambridge, MA, generously pro-
vided the BMP-2-125 plasmid that contains the rhBMP-2 cDNA. A rep-
lication defective, E1 and E3 gene-deleted adenoviral vector was
engineered to encode rhBMP-2 under the human cytomegalovirus pro-
moter (Bosch et al., 2000; Musgrave et al., 2000).
The mc13 and the npmc were transduced with the adenoviral vector
(MOI
 
 5 
 
50). After 4 h of incubation with the adenovirus at 37
 
8
 
C, equal vol-
ume of serum containing media was added to the cell culture for 24 h. The
transduced cells were then trypsinized, centrifuged, washed twice with HBSS, 
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and 0.5–1.0 
 
3
 
 10
 
6
 
 cells were injected into exposed triceps surae of SCID mice
(The Jackson Laboratory) using a 30-gauge needle on a gas-tight syringe. At
14–15 d, animals were killed with cervical dislocation. The injected hind
limbs were analyzed by radiography, and triceps surae were isolated and
flash frozen in 2-methylbutane buffered in PBS, precooled in liquid nitrogen.
The frozen samples were cut into 5–10-
 
m
 
m sections using a cryostat (Mi-
crom, HM 505 E, Fisher Scientific) and stored at 
 
2
 
20
 
8
 
C until further study.
 
Skull Defect Assay
 
3 6–8-wk-old female SCID mice (The Jackson Laboratory) were used in
both the control and experimental groups. The mice were anesthetized
with methoxyflurane and placed prone on the operating table. Using a
number 10 blade, the scalp was dissected to the skull, and the periosteum
was stripped. A 5-mm full-thickness circular skull defect was created using
a dental burr, with minimal penetration of the dura. A collagen sponge
matrix (Helistat™, Colla-Tec, Inc) seeded with 0.5–1.0 
 
3
 
 10
 
6
 
 mc13 cells,
either with or without adBMP-2 transduction, was placed to fill the skull
defect. The scalp was closed using a 4-0 nylon suture, and the animals
were allowed to ad lib food and activity. After 14 d, the mice were killed,
and the skull specimens were analyzed both grossly and microscopically.
For von Kossa staining, slides were fixed in 4% formaldehyde and were
then soaked in 0.1 M AgNo
 
3
 
 solution for 15 min. After exposure to light
for at least 15 min, the slides were washed with PBS and stained with he-
matoxylin and eosin for histological evaluation. The identification of the
mc13 within the newly formed bone in the skull defect was performed us-
ing the LacZ staining. The number of LacZ positive mc13 cells within and
outside the osteoid was consequently monitored.
 
Fluorescent In Situ Hybridization (FISH)
Using Y-probes
 
The FISH technique was used to follow the fate of the injected male npmc
genetically engineered to express BMP-2 into the skeletal muscle of female
mice (Bosch et al., 2000). The Y chromosome-specific probe (Fan et al.,
1996) was biotinylated using a BioNick kit (GIBCO BRL) according to the
manufacturer’s instructions. The hybridized probe was detected with fluores-
cein-labeled avidin (ONCOR, Inc). The nuclei were counterstained with 10
ng/ml ethidium bromide in Vectashield mounting medium (Vector, Inc).
 
Standard Cytogenetic Method for Metaphase 
Preparations of mc13 
 
The standard cytogenetic method for metaphase preparation of mc13 was
performed using a previously described protocol (Barch, 1991). In brief,
the cells were grown to near confluency in a T75 collagen-coated flask in
DME supplemented with 10% horse serum, 10% FBS, 0.5% chick em-
bryo extract, and 1% Pen-Strep solution (all from GIBCO BRL). Cells
had 15 ml of fresh medium added along with 0.2 
 
m
 
g/ml Colcemid solution
(GIBCO BRL) and were allowed to incubate an additional 2 h at 37
 
8
 
C.
Cells were then harvested by adding 0.1% Trypsin-EDTA to the cells un-
til they lifted. Cells were pelleted and resuspended in 5 ml 0.75 M KCl and
incubated 8 min at 37
 
8
 
C. 1 ml Carnoy’s fixative (3:1 methanol to glacial
acetic acid) was next added to solution and the cells pelleted. Fresh fixa-
tive was added and cells were again pelleted. This rinsing and pelleting
was performed three times. Cells were then dropped on glass slides,
heated at 60
 
8
 
C for 30 min and GTG banded. 32 metaphase cells were then
counted for modal number using at 630
 
3
 
. Two images were captured on a
Cytoscan cytogenetics analyzer.
 
Soft Agar Technique
 
The technique of cell growth on soft agar was performed as previously de-
scribed (Tremblay et al., 1991). A 1.275% bacto-Agar (Difco) solution
was first prepared in distilled water and sterilized in an autoclave. The
agar medium containing 20 ml of culture medium at twice the concentra-
tion used was mixed with 20 ml of 1.275% bacto-Agar at 45
 
8
 
C and 10 ml of
FBS. Petri dishes (60 mm) were filled with 5 ml of agar medium and the
agar was allowed to solidify during 1 h at room temperature. The cells to
be tested were trypsinized and resuspended in the culture medium with
15% FBS to obtain a concentration of 500,000 cells per ml. This suspen-
sion was passed twice through a 20 gauge needle to dissociate any aggre-
gate. 1,000,000 cells (2 ml) were then mixed with 5 ml of agar medium. A
sample of 1.5 ml of this agar cell suspension was finally plated over the so-
lidified agar in the Petri dishes. When the new agar layer containing the
cells solidified, 1 ml of culture medium was added to the Petri dishes. The
culture medium overlaying the agar was changed once a week for 2 wk.
The cell behavior was monitored every 2 d and picture was taken. Differ-
ent cell populations were tested: mc13 late passages (
 
.
 
20), mc13 early
passage (
 
,
 
5), HEK293 cells (adenovirus permissive cells), and a freshly
isolated primary myoblast cell culture.
 
Results
 
Characterization of the pp6 Cells In Vitro
 
Cells isolated from primary muscle tissue contain a mixture
of fibroblasts, myoblasts, adipocytes, and hematopoietic
cells. However, the muscle-derived cells can be enriched
using the preplate technique based on their differential ad-
herence characteristics of primary muscle cells to collagen-
coated flasks (Rando and Blau, 1994; Qu et al., 1998; Qu
and Huard, 2000a,b). Cells that are slow to adhere tend to
be morphologically round, express high levels of desmin,
and have the ability to fuse and differentiate into multinu-
cleated myotubes (Rando and Blau, 1994; Qu et al., 1998;
Qu and Huard, 2000a,b). To further analyze the possibility
of the existence of stem cells among the slow adhering
cells, the fractions of slowly adhering, round cells (pp6)
were isolated from 
 
mdx
 
 mice and tested for the expression
of various markers using RT-PCR, immunohistochemis-
try, and flow cytometry (see Table I).
 
Table I. Immunohistochemical, RT-PCR, and Flow Cytometry Analysis of pp6, mc13, MD1, MD2, and Fibroblasts
 
pp6 mc13 MD1 MD2 Fibroblasts
Immuno RT-PCR Flow Immuno RT-PCR Flow Immuno RT-PCR Flow Immuno RT-PCR Flow Immuno RT-PCR Flow
 
Desmin
 
1
 
nd nd
 
1
 
nd nd
 
1
 
nd nd
 
1
 
nd nd
 
2
 
nd nd
CD34
 
11
 
nd
 
22
 
nd
 
11
 
nd
 
11
 
nd
 
22
 
nd
Bcl-2
 
1
 
nd nd
 
1
 
/
 
2
 
nd nd nd
 
2
 
nd nd
 
2
 
nd
 
2
 
nd nd
Flk-1
 
1
 
nd nd
 
1
 
nd nd
 
1
 
nd nd
 
1
 
nd nd
 
2
 
nd nd
Sca-1
 
1
 
nd
 
11
 
nd
 
11
 
nd
 
11
 
nd
 
12
 
nd
 
2
 
M-cadherin
 
2
 
/
 
1
 
nd nd
 
1
 
/
 
2
 
nd nd
 
2
 
nd nd
 
2
 
nd nd
 
2
 
nd nd
Myogenin
 
2
 
/
 
11
 
nd
 
1
 
/
 
21
 
nd nd
 
1
 
nd nd
 
1
 
nd
 
22
 
nd
C-met nd
 
1
 
nd nd
 
1
 
nd nd
 
1
 
nd nd
 
1 nd nd 2 nd
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As shown in Table I, cells in pp6 fractions were express-
ing myogenic markers, including desmin1, MyoD1/2,
myogenin2/1. The pp6 cells were also c-met and MNF pos-
itive (RT-PCR), two genes which are expressed at an early
stage of myogenesis (Miller et al., 1999). The pp6 showed a
lower percentage of cells expressing m-cadherin (2/1), a
satellite cell-specific marker (Irintchev et al., 1994), but a
higher percentage of cells expressing Bcl-2, a marker lim-
ited to cells in the early stages of myogenesis (Dominov et al.,
1998), and CD34, a marker identified in human hemato-
poietic progenitor cells, as well as stromal cell precursors
in bone marrow (Civin et al., 1984; Andrews et al., 1986;
Fina et al., 1990; Simmons and Torok-Sorb, 1991). The pp6
cells were also highly positive for the expression of Flk-1, a
mouse homologue of human KDR gene that was recently
identified as a marker of hematopoietic cells with stem
cell-like characteristics (Ziegler et al., 1999). Similarly, the
pp6 cells were also found positive for Sca-1, a marker
present in subpopulations of both skeletal muscle and he-
matopoietic cells with stem cell-like characteristics (Gus-
soni et al., 1999). Finally, the pp6 cells were also found
CD45 and c-kit negative (see Table I).
Marker Analysis of the Clonal Muscle-derived Cells 
Isolated from pp6
The biochemical markers expressed by mc13 cells were
analyzed using RT-PCR, immunohistochemistry, and flow
cytometry. The markers expressed by mc13 clone were com-
pared with those of pp6 and fibroblasts. As summarized in
Table I, mc13 cells were positive for the expression of
desmin, c-met, MNF, myogenin (1/2), and MyoD (RT-
PCR). These results suggest that this clonal population of
mc13 contained cells at different stages of differentiation.
The mc13 cells were positive for m-cadherin (1/2) and
Bcl-2 (1/2), but negative for CD34 expression. They were
highly positive for the expression of Flk-1 and Sca-1. Simi-
lar to that observed with the pp6 cells, the mc13 cells were
negative for CD45 and c-kit (see Table I).
Two additional clones (MD1/MD2) were also inves-
tigated. These clonal cells have been isolated from the
pp6, but were not transfected with the plasmid to express
b-galactosidase, minidystrophin, and the neomycin resis-
tance gene. These two clones share similarities with mc13
and pp6 since they express desmin, MyoD1, myogenin1,
c-met1, MNF1, and Flk-11 (see Table I). The MD1 and
MD2 cells are also CD452 (see Table I); in contrast to the
mc13, they are positive for CD34 and negative for m-cad-
herin and Bcl-2 (see Table I). The MD1 and MD2 cells
were also compared with the pp6 and mc13 for their ex-
pression of Sca-1 and c-kit. Similar to that observed with
pp6 and mc13, the MD1 and MD2 cells are Sca-11 and
c-kit2 (see Table I).
In Vivo Localization of CD341 and Bcl-21 Cells
To identify the location of CD341 and Bcl-21 cells in vivo,
muscle tissue sections from gastrocnemius of normal mice
were stained using anti-CD34 and anti–Bcl-2 antibodies.
The CD34 positive cells constituted a small population of
muscle-derived cells (Fig. 1 A). Colocalization of CD34
expressing cells (Fig. 1 A) with laminin, which stained the
basal lamina (Fig. 1 B), revealed the location of these
CD341 cells within the basal lamina (Fig. 1, C and D). The
colocalization of the CD341 cells with a nuclear staining
(Hoescht 33258) indicated the presence of cells instead of
small blood vessels that are also positive for CD34 (Fig. 1,
C and D). In fact, the expression of CD34 by vascular en-
dothelial cells has been shown in previous studies (Fina
et al., 1990). The Bcl-2 expressing cells (Fig. 1 E) were
colocalized with collagen type IV (Fig. 1 F) and identified
within the basal lamina (Fig. 1 G). The Bcl-2 expressing
cells were also colocalized with a nuclear staining (Fig. 1
G; Hoechst 33258). The sections were stained for m-cad-
herin to identify the location of satellite cells (Fig. 1 H).
The satellite cells were identified at similar locations as
CD341 and Bcl-21 cells (Fig. 1 H, arrow). The expression
of BCL-2 (Fig. 1 E), as well as m-cadherin (Fig. 1 H) was
not found uniformly distributed in the cell membrane.
Multiple attempts to colocalize CD34 or Bcl-2 with m-cad-
herin were unsuccessful, suggesting that m-cadherin ex-
pressing cells do not express either Bcl-2 or CD34. This is
consistent with our result that pp6, which express CD34
and Bcl-2, but express minimal levels of m-cadherin2/1
(see Table I). Similarly, mc13 are expressing m-cadherin
(1/2) and are negative for CD34 (see Table I).
In Vitro Differentiation of Clonal Muscle Stem Cells 
into Osteogenic Lineage
To further characterize the subpopulation of muscle-
derived cells that may have stem cell-like capabilities, the
mc13 clone isolated from the pp6 population was further
subjected to in-depth analysis. We investigated whether
mc13 cells have the potential to differentiate into different
lineages by examining their response to rhBMP-2 stimula-
tion. The cells were plated on a 6-well culture dish in iden-
tical density and allowed to become confluent with and
without exposure to 200 ng/ml rhBMP-2. Within 3–4 d,
there was a striking morphologic difference between mc13
cells exposed to rhBMP-2 and control cells. Without stim-
ulation of rhBMP-2, mc13 cells started to fuse into multi-
nucleated myotubes (Fig. 2 A). When exposed to 200 ng/ml
rhBMP-2, however, cells remained mononucleated and
did not fuse (Fig. 2 B). When cell density reached .90%
confluency, the untreated culture fused to form multiple
myotubes (Fig. 2 C), whereas the treated cells became cir-
cular and hypertrophic (Fig. 2 D, see arrows). Using im-
munohistochemistry, these hypertrophic cells were ana-
lyzed for the expression of osteocalcin. Osteocalcin is a
matrix protein that is deposited on bone, specifically ex-
pressed by osteoblasts. These hypertrophic cells in the
rhBMP-2–treated mc13 were found highly positive for ex-
pression of osteocalcin (Fig. 2 E, see arrows). This suggests
that the rhBMP-2–stimulated mc13 cells can no longer
fuse into myotubes and differentiate into osteoblasts.
We monitored the level of desmin as mc13 cells undergo
morphologic differentiation with rhBMP-2 stimulation as
described above. Freshly isolated mc13 cells were uni-
formly positive for desmin (Fig. 3, A and B). However,
within six days of exposure to rhBMP-2, the percentage of
desmin positive cells significantly decreased to 30–40%
(*P , 0.05), whereas the control cells not exposed to
rhBMP-2 remained 90–100% desmin positive (Fig. 3 C).
This result indicates that a large number of mc13 cells loseThe Journal of Cell Biology, Volume 150, 2000 1090
their desmin expression upon stimulation with rhBMP-2
(Fig. 3 C). It is unclear whether this decrease in percentage
of desmin positive cells was due to increased proliferation
of a small number of cells that lose desmin expression or
due to a large number of cells responding to rhBMP-2.
However, in light of the complete absence of multinucle-
ated myotubes in flasks containing rhBMP-2, it seems more
likely the decreased percentage of desmin positive cells is
due to the loss of myogenic characteristics of mc13 cells.
We also tested for alkaline phosphatase activity in
rhBMP-2–stimulated mc13 cells. The alkaline phosphatase
activity has been used as a biochemical marker for cells
differentiating in osteoblastic lineage (Katagiri et al., 1995).
As shown in Fig. 3 D, alkaline phosphatase expression of
mc13 cells, in contrast, increased .600-fold in response to
rhBMP-2. The npmc did not give rise to increased alkaline
phosphatase activity in response to rhBMP-2 (Fig. 3 D).
Taken together, these data demonstrate that mc13 cells
Figure 1. Colocalization of
CD34 and Bcl-2 positive cells
with laminin/collagen type IV.
Muscle sections from normal
mice were stained with anti-
CD34 antibody and visual-
ized with fluorescence (A, ar-
row). The sections were co-
stained with antilaminin
antibody to outline the basal
lamina (B, arrowhead), and
Hoechst to demonstrate nu-
clei (C and D, blue fluores-
cence). The CD34 positive
cells were located within the
basal lamina (C and D). The
muscle sections were also
stained with Bcl-2, collagen
type IV, and Hoechst in a simi-
lar manner. The Bcl-2 positive
cells (E, arrow), which colocal-
ized with nuclei staining (G),
were found located within the
basal lamina (F and G).
M-cadherin  staining showed
that satellite cells are found
beneath the basal lamina at
similar locations as CD341 or
Bcl-21 cells (H). Bar: (A–C,
E–H) 10 mm; (D) 25 mm.Lee et al. Characterization of Muscle-derived Stem Cells 1091
lose the expression of desmin and do not fuse into myo-
tubes, but differentiate into an osteogenic lineage in re-
sponse to rhBMP-2 in vitro.
In Vivo Differentiation of mc13 Cells into Myogenic 
and Osteogenic Lineages
To assess the in vivo characteristics of mc13 cells, the cells
were intramuscularly injected into hind limb musculature
of mdx mice to determine whether these clones were capa-
ble of differentiating through the myogenic lineage in vivo.
The b-galactosidase and dystrophin expression were fol-
lowed to confirm the ability of mc13 cells to enhance mus-
cle regeneration and partially restore dystrophin. Before
injection, LacZ staining of the stably transfected mc13 re-
vealed that 90–100% of cells were expressing b-galactosi-
dase (data not shown). 5 3 105 mc13 cells were injected in-
tramuscularly in the hind limb muscles of mdx mice; the
animals were killed at 7 d after transplantation. The hind
limbs of the injected animals were harvested for histology
and immunohistochemical analysis. Multiple LacZ (Fig. 4 A)
and dystrophin positive myofibers (Fig. 4 B) were readily
identified at the injection site (Fig. 4, A and B). We have
monitored the number of myofibers that coexpress LacZ/
dystrophin and found 379 6 256 positive myofibers at 7 d
after injection (Fig. 4 E). This demonstrates that mc13 cells,
when injected into the dystrophin deficient mdx mice, can
differentiate through the myogenic lineage in vivo and con-
sequently enhance muscle regeneration and partially re-
store dystrophin expression in the dystrophic muscle.
More importantly, we have tested whether mc13 cells can
be systemically delivered to dystrophic muscles. The mc13
cells (5 3 105) were intravenously injected in the tail vein
of mdx mice, and the animals were killed at 7 d after injec-
tion. We observed a small number of LacZ positive myofi-
bers (Fig. 4 C) coexpressing dystrophin in the hind limb of
the injected animals (Fig. 4, C and D, asterisk). A lower
number of LacZ and dystrophin positive myofibers were
observed after the systemic delivery of the mc13 cells
when compared with the i.m. injection (Fig. 4 E). This re-
sult suggests that mc13 cells can be delivered systemically
to the target tissue for partial restoration of dystrophin ex-
Figure 2. Morphologic
change and expression of os-
teocalcin by mc13 cells with
exposure to rhBMP-2. Mc13
cells were incubated in
growth media without
rhBMP-2 for 6 d. When cells
became  .50% confluent,
they began to fuse and form
multinucleated myotubes
(A). When mc13 cells were
incubated in growth media
containing 200 ng/ml rhBMP-2,
cells remained mononucle-
ated and did not fuse (B).
When cells reached .90%
confluency without rhBMP-2,
almost all the cells fused to
form myotubes (C). With
rhBMP-2, when cells reached
.90% confluency, round,
hypertrophic cells began to
appear in the culture (D, ar-
rows). These round, hyper-
trophic cells were highly posi-
tive for osteocalcin expression
(E, arrows). Bar, 50 mm.The Journal of Cell Biology, Volume 150, 2000 1092
pression. We have also investigated whether the mc13 cells
were also disseminated in other tissues by testing the pres-
ence of dystrophin positive cells in nonmuscle tissues of
the injected animals. We have been unable to detect any
dystrophin positive cells in the lung, spleen, liver, kidney,
and brain of the injected animals at 7 d after injection
(data not shown).
The colocalization of dystrophin and b-galactosidase ex-
pression in the membrane of various myofibers after i.m.
and i.v. injection of mc13 is unclear. In fact, some myofi-
bers display a different level of b-galactosidase expression
in the membrane versus the cytoplasm, whereas other myo-
fibers are b-galactosidase negative in the cytoplasm and
positive in the membrane. The potential fusion of b-galac-
tosidase with dystrophin and their transport to the mem-
brane may explain this predominance of b-galactosidase ex-
pression in the membrane.
To test the pluripotent characteristics of mc13 in vivo, the
cells were transduced with an adenoviral vector encoding
rhBMP-2 (adBMP-2). The mc13 cells were then injected
into hind limbs of SCID mice, and bone formation was
monitored radiographically and histologically at 14–15 d af-
ter injection. The LacZ and dystrophin were assessed in
vivo to follow the fate of the injected cells. Previous exper-
iments have shown that 70–90% of these cells are typically
successfully transduced with our adenoviral vectors (our
unpublished data). ELISA of mc13 cells transduced with
adBMP-2 showed that infected cells are capable of pro-
ducing a significantly higher amount of rhBMP-2 (*P ,
0.05) when compared with control cells that were not
transduced by the vector (Fig. 5 A). The BMP-2 detected
in the nontreated cells with the ELISA technique is attrib-
uted to nonspecific background detection. Radiographic
analysis of hind limbs of injected SCID mice revealed ro-
bust ectopic bone formation within 14 d of injection (Fig. 5
B, see arrow). Histologic analysis using LacZ staining of
the ectopic bone showed that LacZ positive mc13 cells
were uniformly located within the mineralized matrix or
lacunae, a typical location where osteoblasts and osteo-
cytes are found (Fig. 5 C). To further confirm the role of
mc13 in formation of the ectopic bone, the muscle sections
were also stained for the expression of dystrophin. As
shown in Fig. 5 D, the ectopic bone contained cells highly
positive for dystrophin, further implicating that mc13 cells
are intimately participating in bone formation.
To determine whether the genetically engineered mc13
expressing BMP-2 can express bone protein, we have colo-
calized b-galactosidase expressing nuclei, osteocalcin ex-
pression, and nuclei staining (DAPI) by immunohistochem-
istry (Fig. 5, E–H). We have identified nuclei expressing
b-galactosidase (Fig. 5 F, FITC/green, see arrow), which
express osteocalcin (Fig. 5 G, cy3/red, see arrow), and
colocalized with nuclei staining (Fig. 5 E, DAPI/blue, see
arrow). The triple colocalization of DAPI/osteocalcin and
b-galactosidase (Fig. 5 H, see arrow) suggest that the ge-
netically engineered mc13 can differentiate in bone lin-
eage and consequently express bone protein (osteocalcin).
We were also capable of detecting b-galactosidase ex-
pressing cells (Fig. 5 F, arrowhead) that were not colocal-
ized with osteocalcin positive cells (Fig. 5 G, arrowhead),
suggesting that some of the injected mc13 were not ex-
pressing osteocalcin (Fig. 5, E–H, arrowheads).
As a control, similar experiments were carried out with
male npmc, which are highly fibroblastic in nature. We
have observed that npmc genetically engineered to ex-
press BMP-2 also supported robust ectopic bone forma-
tion in skeletal muscle (Fig. 6 A). The FISH technique was
used to identify the Y chromosome positive cells and re-
vealed that the injected npmc cells were located, in con-
trast to mc13, outside of the osteoid (Fig. 6 B, arrow); a
complete absence of Y chromosome positive cells was
found within the newly formed osteoid (Fig. 6 C, arrow-
heads). This suggests, as previously described by our
group (Bosch et al., 2000; Musgrave et al., 2000), that the
npmc are capable of delivering rhBMP-2 to form ectopic
bone, but are unable to differentiate into osteoblasts. In
Figure 3. The effect of rhBMP-2 on the ex-
pression of desmin and alkaline phos-
phatase by the mc13 cells. Desmin staining
of freshly isolated mc13 clones (A) showed
that all of these cells express desmin. The
phase-contrast view (B) is shown to demon-
strate that a high percentage of the cells
were desmin positive. Mc13 cells were incu-
bated in growth media containing 200 ng/ml
rhBMP-2 for 6 d. Cells were then stained for
desmin expression, and percent desmin pos-
itive cells calculated by visualization with
immunofluorescence. As a control, mc13
cells were grown in parallel without addi-
tion of rhBMP-2. When grown without
rhBMP-2, mc13 cells remained uniformly
(90–100%) desmin positive (C). With expo-
sure to rhBMP-2, there is a significant de-
crease (*P , 0.05) in relative number of
desmin positive cells (30–40%) within 6 d
(C). The npmc and mc13 cells were also an-
alyzed for expression of alkaline phos-
phatase after 6 d of growth with and without exposure to 200 ng/ml rhBMP-2. With rhBMP-2 stimulation, mc13 cells show a .600-fold
increase in alkaline phosphatase activity than nonstimulated cells (D). The npmc show only minimal alkaline phosphatase activity with
or without rhBMP-2 (D). *, Indicates a significant difference using the t test (P , 0.05). Bar, 100 mm.Lee et al. Characterization of Muscle-derived Stem Cells 1093
this case, the cells participating in mineralization of the ec-
topic bone are most likely from the host tissue. This con-
firms that the capacity to differentiate into osteoblasts,
both in vivo and in vitro, is inherent to highly purified
muscle-derived cells such as mc13.
Enhancement of Bone Healing by Genetically 
Engineered mc13 Cells
To test the clinical applicability of our findings and to further
support the functional properties of mc13, we investigated
whether the mc13 cells engineered to express BMP-2 can
be used to enhance healing of a bone defect. We created
5-mm skull defects in skeletally mature (6–8-wk-old) fe-
male SCID mice using a dental burr. A 5-mm size skull de-
fect has been shown to be a nonhealing defect in previous
mouse models (Krebsbach et al., 1998). This skull defect
was filled with a collagen sponge matrix that was seeded
with mc13 cells with or without adBMP-2 transduction.
The SCID mice were killed at 14 d, and the healing of the
skull defect was analyzed both grossly and microscopi-
cally. As shown in Fig. 7 A, the control group treated with
mc13 cells that were not transduced to express rhBMP-2
shows no evidence of healing of the defect (see arrows
showing the edge of the bone defect). The experimental
group treated with mc13 transduced to express rhBMP-2
shows a full closure of the skull defect at two weeks (Fig. 7
B). The von Kossa staining, which highlights mineralized
bone, shows robust new bone formation in the group
treated with mc13 transduced to express rhBMP-2 (Fig. 7
D), but little evidence of new bone formation by the con-
trol group (Fig. 7 C, see arrow to indicate the defect site).
The area of new bone in the experimental group injected
with mc13 engineered to express BMP-2 (Fig. 7 D, square
E), was also analyzed by LacZ staining to determine
whether the transplanted cells were participating in the
bone formation. As shown in Fig. 7 E, LacZ positive nuclei
were identified within the newly formed bone (arrows), in-
dicating active participation of transplanted cells in bone
formation under the influence of rhBMP-2. Greater than
95% of the LacZ positive mc13 cells were found inte-
grated within the newly formed bone. LacZ negative cells
were also identified within the newly formed skull indicat-
ing participation of host-derived cells. This experiment
shows that mc13 can be induced to differentiate into os-
teoblasts and consequently, be used to heal a nonhealing
bone defect under the influence of rhBMP-2.
Standard Cytogenetic and Tumorigenicity Assay
on mc13
We have also investigated the karyotype of these cells and
tested whether they can be grown in soft agar as an indicator
of their tumorigenicity (not illustrated). The mc13 cells ana-
Figure 4. In vivo differentiation of mc13
cells into myogenic lineage after i.m. and
i.v. injection. The mc13 cells were stably
transfected with a plasmid DNA con-
struct encoding LacZ, dystrophin, and
neomycin resistance genes and injected
intramuscularly into hind limbs of mdx
mice. After 7 d, mice were killed and
hind limb musculature was isolated for
histology. Many LacZ positive myofibers
(A) were found at the injected site that
colocalized with dystrophin positive myo-
fibers (B). Some LacZ (C,*) and dystro-
phin positive myofibers (D,*) were also
found in the hind limb muscle of mdx
mice after i.v. injection of mc13. The
number of myofiber that coexpressed
LacZ and dystrophin was counted (E)
and compared between the i.m. (IM)
and i.v. (IV) groups. Bar: (A and B) 100
mm; (C and D) 50 mm.The Journal of Cell Biology, Volume 150, 2000 1094
lyzed had an unknown passage history, but likely over 20
passages. The normal diploid number of chromosomes (2n)
seen in mice (Mus musulus) is 40 (Francke and Nesbitt,
1971). The majority of cells counted in our clone was 40 with
few cells missing 1–4 chromosomes (known as hypodip-
loidy). Also observed were tetraploid (4n) cells (metaphase
with 80 chromosomes). The hypodiploid and tetraploid cells
are probably due to normal tissue culture artifact (Barch,
1991). In fact, tetraploidy is commonly seen in cultured cells
and the hypodiploidy is often the result of mechanical over-
spreading of the metaphase cells when making the slides, re-
sulting in a loss of a chromosome(s) (Barch, 1991).
Figure 5. In vivo differentiation
of mc13 cells into osteogenic lin-
eage after genetic engineering to
express BMP-2. The amount of
BMP-2 secreted by the mc13
cells that were transduced with
adBMP-2 was found significantly
higher (*P , 0.05) than the non-
transduced mc13 cells (A). 0.5–
1.0 3 106 cells genetically engi-
neered to express BMP-2 were
injected into hind limbs of SCID
mice. After 14 d, mice were
killed, and the hind limb muscle
tissues were analyzed radio-
graphically for evidence of bone
formation. There was a robust
ectopic bone formation (seen ra-
diographically) within skeletal
muscle in all mice injected with
mc13 cells transduced with
adBMP-2 (B, arrow). The in-
jected muscle containing the ec-
topic bone was then harvested
and stained for b-galactosidase
activity to locate injected cells.
The LacZ positive cells were
uniformly found within the la-
cunae, a location where osteo-
blasts and osteocytes are nor-
mally found (C). The ectopic
bone was also stained for pres-
ence of dystrophin. As indicated
by green fluorescence, the ec-
topic bone contained abundant
cells expressing dystrophin, con-
firming that mc13 cells were ac-
tive participants in formation of
bone (D). To determine whether
the genetically engineered mc13
expressing BMP-2 can express
bone protein, we colocalized
b-galactosidase expressing nu-
clei, osteocalcin expression, and
nuclei staining (DAPI) by immu-
nohistochemistry (E–H). We
identified nuclei expressing
b-galactosidase (see Fig. 6 F,
arrow, FITC/green) that ex-
pressed osteocalcin (see Fig. 6 G,
arrow, cy3/red) and colocalized
with nuclei staining (see Fig. 6 E,
arrow, DAPI/blue). The triple
colocalization of DAPI/osteocal-
cin and b-galactosidase (Fig. 6
H, arrows) suggests that the ge-
netically engineered mc13 can
express bone protein (osteocalcin). We have also observed b-galactosidase expressing nuclei (Fig. 6 F, arrowhead) that were not colo-
calized with osteocalcin expressing cells (Fig. 6 G, arrowhead), suggesting that some of the engineered mc13 were not expressing osteo-
calcin (Fig. 6, E–H, arrowheads). Bar: (C and D) 50 mm; (E–H) 25 mm.Lee et al. Characterization of Muscle-derived Stem Cells 1095
The soft agar test (Tremblay et al., 1991) was addition-
ally performed to characterize whether the mc13 can grow
on soft agar as an indicator of malignant processes within
the cell population. The mc13 used for this experiment
were totally incapable of growing on soft agar. In fact, we
compared these data with a very early passage of the mc13
and, similarly, they were not capable of growing in soft
agar. As a positive control, we used the HEK293 cells (ad-
enovirus permissive cells), which grew vigorously and pre-
sented large cellular clumps. Our negative control was a
freshly isolated primary myoblast cell isolation that dis-
played no growth and consequently no evidence of tumor-
igenicity. To further substantiate that these cells are not
tumorigenic, we have never histologically observed any
adverse effect(s), such as tumor development, after their
injection in SCID mice skeletal muscle or other tissues, in-
cluding the bone defect model.
Discussion
We have observed that the preplate technique enriches for
a population of muscle-derived cells that express both
early myogenic markers, including desmin, c-met, MNF,
and Bcl-2, and stem cell markers (Sca-1, Flk-1, CD34). In
vivo staining showed that these cells were localized within
the basal lamina, a location normally occupied by satellite
cells. Clonal analysis from these highly purified muscle-
derived cells (pp6) showed that, as observed with the pp6
cells (Bosch et al., 2000), the mc13 clonal cells are able to
differentiate into myogenic, as well as osteogenic lineage,
in vitro and in vivo. The marker analysis of the clone
showed expression of both stem cell and satellite cell
markers, including m-cadherin, Flk-1, and Sca-1. The i.m.
as well as i.v. injection of mc13 can enhance muscle regen-
eration and partially restore dystrophin in mdx mice. Fi-
nally, the genetic engineering of the mc13 to express os-
teogenic protein (BMP-2) was capable of enhancing the
healing of a skull defect in SCID mice.
An immortalized clonal cell line from mouse myoblast,
C2C12, has been shown to decrease expression of myoge-
nin and MyoD mRNA, and increase expression of alkaline
phosphatase, osteocalcin, and parathyroid-dependent 39,
59-cAMP in response to rhBMP-2 in vitro (Katagiri et al.,
1995). However, no in vivo data with C2C12 cells are
available. Our marker analysis with RT-PCR, as well as
immunohistochemistry, shows that C2C12 cells are also
Flk-12, m-cadherin2, and c-met2 (not shown). This sug-
gests that mc13 cells are different from C2C12 cells. In ad-
dition, morphologically, C2C12 cells are polygonal and fi-
broblast-like, whereas mc13 cells are small and round
when cultured in a monolayer system. Whether mc13 cells
and C2C12 cells represent a completely distinct subgroup
of cells or a different maturation stage of the same popula-
tion is still unknown.
A recent in vivo study has demonstrated that in human
hematopoietic cells, CD341KDR1 population had the
highest pluripotent characteristics (Ziegler et al., 1999).
The mouse homologue of KDR is Flk-1. The mc13 popula-
tion is Flk-11, similar to the human hematopoietic pluripo-
tent cells. However, mc13 cells express myogenic markers
such as desmin, MyoD, myogenin, c-met, and MNF, and
they are CD342, indicating that these cells are distinct
from the hematopoietic stem cells. The expression of myo-
genic markers indicative of both early (c-met, desmin,
MNF, and Bcl-2) and late stage of myogenesis (myogenin,
MyoD) is probably related to the myogenic differentiation
of some muscle-derived cells within the mc13 population
with the cell culturing.
Interestingly, the pp6 cells are CD341, whereas mc13
cells are CD342. However, we cannot rule out that mc13
initially expressed CD34, but the extensive selection with
G418 may have differentiated the mc13 clone, resulting
consequently in their loss of CD34 and the gain of m-cad-
herin expression. In fact, we have recently investigated two
new clones (MD1 and MD2) from the pp6 to determine
whether the marker expression by the mc13 were unique
or also expressed by other clonal cell populations origi-
nated from the same pp6 population. These clonal cells
have been isolated from the pp6, but were not genetically
engineered with the plasmid to express b-galactosidase
and dystrophin. These two clones were similar to mc13 for
most of the myogenic and stem cell marker expression in
vitro, but in contrast to mc13, they are positive for CD34
and negative for m-cadherin, as well as Bcl-2. These re-
Figure 6. The inability of BMP-2 expressing npmc to differentiate into osteogenic lineage. The npmc were isolated from a male mdx
mouse and injected in the hind limb muscle of a female SCID mice. We have observed that npmc genetically engineered to express
BMP-2 also leads to ectopic bone formation when injected in skeletal muscle. A, The FISH technique was used to identify the Y chro-
mosome positive cells (donor cells) and revealed that the injected cells were located outside of the osteoid (B, arrow); a complete ab-
sence of Y chromosome positive cells was found within the newly formed osteoid (C, arrows). These cells were therefore incapable of
differentiating into osteogenic lineage in vivo. Bar: (A) 100 mm; (B and C) 50 mm.The Journal of Cell Biology, Volume 150, 2000 1096
sults suggest that mc13 might be isolated from a small pop-
ulation of CD342 cells within the pp6 population or the
mc13 were originally CD341, but during the selection,
they differentiated into CD342 cells.
Although the expression of CD34 can account for a dif-
ference between the mc13 and pp6/MD1/MD2, recently it
has been published (Goodell, 1999; Sato et al., 1999) that
the expression of CD34 is reversible on hematopoietic stem
cells. In fact, these papers suggest that CD34 is probably a
marker of activated stem cells, but it is not necessarily ex-
pressed in all stem cells. Although the reversible expres-
sion of CD34 remains to be determined in muscle-derived
stem cells, the use of CD34 as a marker of muscle-derived
stem cells should at least be used with caution.
The relationship between mc13 and other populations
of muscle-derived stem cells, such as the side population
(SP) of muscle-derived cells described by Gussoni et al.
(1999), was also investigated. The SP population of cells
from Gussoni et al. (1999) derived from muscle was
Sca-11, cKit2, CD432, CD452, Lin2, CD342. The mc13
are CD342, Bcl-21/2, Flk-11, Sca-11, m-cadherin1/2,
myogenin1/2, c-met1, MNF1, c-kit2, and CD452. Al-
though mc13 is highly similar to the muscle-derived SP
cells, more markers (especially myogenic markers for the
SP cells) should be characterized to determine their rela-
tionship. Similarly, a recent paper by Jackson et al. (1999)
also described a new population of muscle-derived stem
cells that express stem cell antigens (Sca-1 and cKit) and
lack CD45. However, based on their methodology, the
cells used for the experiments were derived from the pp2.
Since the mc13 was isolated from the pp6 and the mc13 are
c-Kit2, we believe that mc13 are different than the muscle-
derived cells described by Jackson et al. (1999). In fact, the
cells isolated at pp2 in our experiments are highly different
than the cells isolated at pp6 in term of marker expression
in vitro as well as their functional properties in vivo (Qu et al.,
1998). Clearly, more studies are required to accurately as-
sess the origin and, more importantly, the functional prop-
Figure 7. Enhancement of bone heal-
ing by rhBMP-2 producing mc13 cells.
A 5-mm skull defect was created in a
SCID mice using a dental burr, and
the defect was filled with a collagen
sponge seeded with mc13, with or
without adBMP-2 transduction. The
mice were killed at 14 d and analyzed
grossly and microscopically for healing
of the defect. A gross specimen from
the control group was treated with col-
lagen sponge seeded with mc13 with-
out adBMP-2. At 14 d, there was no
apparent healing of the skull defect
(A, arrows). A representative speci-
men from mice treated with collagen
sponge seeded with mc13 transduced
with adBMP-2 (B). There was almost
a complete closure of the defect within
14 d (B). A von Kossa staining of the
histological specimen from the control
group showed no evidence of new
bone formation (C, arrow shows de-
fect site). von Kossa stain of the
adBMP-2–treated group showed ro-
bust bone formation at 14 d (D). The
mc13 cells transduced with adBMP-2
were followed using the LacZ staining
(E). The vast majority of the b-galac-
tosidase expressing nuclei (.95%)
was found within the newly formed
bone (E, arrows). Bar: (C and D) 100
mm; (E) 50 mm.Lee et al. Characterization of Muscle-derived Stem Cells 1097
erties of these various population of muscle-derived stem
cells.
The relationship of the clonal mc13 cells with satellite
cells is still unclear, but various features of these cells sug-
gest a close relationship with satellite cells. These features
include: the expression of myogenic markers including
m-cadherin, which is known as a specific marker for satel-
lite cells by the mc13 cells (Irintchev et al., 1994); the myo-
genic ability of the mc13 to differentiate into myotubes in
vitro and regenerate skeletal muscle in vivo; and the loca-
tion of Bcl-2 expressing cells within the basal lamina,
where the satellite cells are normally located, also suggest
a close relationship of mc13 with the satellite cells, espe-
cially knowing that mc13 are Bcl-21/2. Additional studies
are required to determine the origin of mc13 and conse-
quently elucidate their relationship with satellite cells.
Although mc13 can efficiently regenerate skeletal mus-
cle after i.m. injection, their ability to migrate to skeletal
muscle after i.v. injection remains an important feature of
these cells. Whereas a lower number of LacZ and dystro-
phin positive myofibers were found after i.v. injection of
mc13 when compared with the i.m. injection, the mecha-
nism by which these cells can be disseminated by the
bloodstream and return to the skeletal muscle is important
and requires further investigation. The development of ap-
proaches to improve the systemic delivery of these cells
will be investigated. The absence of dystrophin positive
cells at 7 d after injection within the lung, liver, spleen, kid-
ney, and brain after i.v. injection of mc13 is surprising.
These results suggest that the injected cells get specifically
disseminated in the skeletal muscle, although we cannot
rule out that the injected cells were present on these non-
muscle tissues at an early time point after injection, but
died in the nonmuscle tissue.
The number of positive myofibers found in the injected
animals after i.m. and i.v. injection of mc13 was also com-
pared with that reported by Beauchamps et al. (1999) and
Gussoni et al. (1999). In fact, the number of dystrophin
positive myofibers found in the injected muscle after i.m.
injection of 500,000 mc13 cells led to 379 6 256 dystro-
phin/LacZ positive myofibers; only 16 6 7 dystrophin/
LacZ positive myofibers were found after i.v. injection of
the same number of mc13 cells. The number of dystrophin
positive myofibers in our experiment after the i.v. injec-
tion was slightly lower to the i.v. injection of muscle-
derived SP cells as described by Gussoni et al. (1999). Var-
ious factors may have accounted for the slight difference
of cell transfer between the two cell populations including:
different populations of muscle-derived cells or a different
stage of maturation of a similar population of cells; the
times after injection; and the irradiation treatment that
may improve the success of myoblast transfer (Morgan et
al., 1990, 1993).
We have also compared our results with a recent publi-
cation from Beauchamps et al. (1999). They reported that
only 1% of the injected cells persisted at 24 h, but an ex-
tensive proliferation of the surviving population equivalent
to 23.5% of the initial population of cells were observed at
four days after injection. The extensive proliferation of
this small fraction of cells led to the formation of a large
number of dystrophin positive myofibers at three weeks
after injection. Although the number of dystrophin posi-
tive myofibers is not available, these results are also sim-
ilar to our current data, as well as to data previously re-
ported by our group (Qu et al., 1998). In fact, by counting
the number of m-cadherin and CD34 positive cells, we
have approximated that the purified cells (pp6) represent
about one percent of the satellite cell population. The i.m.
injection of these highly purified cells also leads to a signif-
icant enhancement of myoblast transfer when compared
with regular myoblasts (Qu et al., 1998).
The presence of stem cells in skeletal muscle makes this
tissue an attractive source of cells for cell-transplantation
therapy to enhance the healing of various tissues of the
musculoskeletal system. We have in fact investigated in
this study whether the genetic engineering of mc13 cells to
express rhBMP-2 can be used to enhance closure of a non-
healing skull defect. Our results suggest that the mc13 was
capable of inducing and, more importantly, participating
in ectopic and orthopic bone formation when genetically
engineered to express BMP-2. It is likely that the trans-
planted muscle cells are acting as a delivery vehicle for
rhBMP-2, as well as a source of cells that differentiate into
osteoblasts. The observation that 95% of the transplanted
mc13 genetically engineered to express BMP-2 are located
within the newly formed bone suggests that the vast ma-
jority of these cells are differentiating into osteogenic
lineage and participating in bone formation. Based on
these results, the stimulation with BMP-2 is required to
differentiate these mc13 cells in osteogenic lineage to con-
sequently improve bone healing. Our data suggest that the
mc13 will differentiate into skeletal muscle, but the addi-
tion of an extra stimuli, such as the BMP-2 used in this ex-
periment, will push them to differentiate in osteogenic lin-
eage. These results suggest that muscle tissue is a valuable
resource for osteoprogenitor cells to be used in clinical set-
ting to improve bone healing.
Finally, we have investigated the karyotype of these
cells and tested whether they can be grown in soft agar as
an indicator of their tumorigenicity. Our results suggest
that the number of chromosomes within the mc13 cells are
normal and more importantly, they are totally incapable of
growing on soft agar. This result, in addition to the lack of
any adverse effect(s), at least histologically, such as tumor
development, after their injection (mc13) in either skeletal
muscle or other tissues in immunodeficient SCID mice,
suggest that the mc13 are not tumorigenic.
In summary, the isolation and purification of muscle-
derived stem cells offers an opportunity to elucidate cellular
and molecular mechanisms of organogenesis. Taken to-
gether, our results suggest the isolation of a clonal popula-
tion of muscle-derived stem cells capable of improving both
muscle regeneration and bone healing. These new results
will shed more light on the functional properties of the mus-
cle-derived stem cells and further support that muscle tissue
may become a valuable resource for the isolation of os-
teoprogenitor cells capable of improving bone healing. Fur-
ther characterization of these muscle-derived stem cells will
open an array of possibilities for advancement of tissue en-
gineering and tissue transplantation techniques.
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